

Next Generation Site-Specific Conjugation and Linker Technologies for ADCs
AJICAP®’s VALUE
Therapeutic Window Enhancement
- ADCs with higher efficacy and lower toxicity achieved by site-specific conjugation and stable & hydrophilic linker
Straightforward Site-Specific Conjugation Method
- Direct modification on native antibody by chemical method
- No genetic engineering and no enzyme required
- Simple and high yield manufacturing process
- Precisely controlled DAR2 and higher
Applicable for Versatile ADCs
- Site-specific conjugation applicable for any IgG molecule and a variety of payloads
- Stable & hydrophilic linker compatible with various payloads


Index
Technology
AJICAP® Site-Specific Conjugation
AJICAP® site-specific conjugation is an innovative direct chemical site-specific conjugation method for intact native antibodies, offering significant advantages for next generation ADCs.

AJICAP® Site-Specific Conjugation consists of:
Introduction of bio-orthogonal functionalities (thiol, azide etc) onto specific Lys residue in Fc region*
Conjugation with
linker-payload
Advantage of AJICAP® Site-Specific Conjugation
Higher efficacy and lower toxicity achieved due to site-specificity
Simple manufacturing and purification process providing CMC advantage
Precisely controlled DAR2 or higher DAR on specific sites
Applicable for a wide variety of antibodies i.e. IgG1, IgG2 and IgG4
Compatible with various payload-linkers i.e. small molecule to large molecule
Application of AJICAP® Site-Specific Conjugation:
ADC platform with various payloads (toxin and others)
In-vivo radio imaging/therapy platform with radioisotopes
Long-acting biopharmaceutical platform for peptides and oligonucleotides
Bispecific platform with proteins

AJICAP® Stable and and Hydrophilic Linker
AJICAP® linker is a novel stable and hydrophilic linker, applicable to various payloads, offering significant advantages for versatile ADCs.

Characteristics of AJICAP® stable and hydrophilic linker
Higher serum stability and controlled release in cancer tissues
Hydrophilic masking of payload
Advantage of AJICAP® Stable and Hydrophilic Linker
Higher efficacy and lower toxicity achieved due to higher serum stability and controlled release in cancer tissues
Dramatically lower aggregation of ADCs by hydrophilic masking of payloads
Applicable for a variety of conjugation technologies including AJICAP® conjugation
Application of AJICAP® Stable and Hydrophilic Linker Technology:
Compatible with a variety of conjugation technologies including:
AJICAP® Site-Specific Conjugation Technology

Native Cys conjugation
DAR4-DAR8

Other genetic engineering and
enzymatic method

Biological Activity of AJICAP®-ADCs
ADCs generated by AJICAP® site-specific conjugation and stable & hydrophilic linker has higher efficacy and lower toxicity.

Global Service Offering
Service flow of AJICAP® is simple and easy. The following steps outline the process:


Service Flow
Service flow of AJICAP® is simple and easy. The following steps outline the process:

Research plan discussion
Client ships antibody (and payload) to Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services generates ADCs or other conjugates
Client evaluates ADCs or conjugates in vitro and in vivo
Technology license Go/No Go decision
GxP production discussion
Contact Us
For further information, please contact us using the link below and an Ajinomoto Bio-Pharma Services representative will contact you.